View PDF
Over
the years, the Division of HIV/AIDS Prevention (DHAP)
at the Centers for Disease Control and
Prevention (CDC) has developed a comprehensive
program of HIV surveillance to collect, analyze,
and disseminate data on HIV infection and AIDS.
Through HIV surveillance, DHAP monitors many
facets of the trends in HIV in the United
States.
This fact sheet contains information on the HIV
surveillance that DHAP currently supports. The
data inform and guide the critical decisions
that ensure HIV prevention funds are directed to
those populations most affected by the disease.
HIV Case Surveillance
In 1981, CDC first reported cases of a rare
pneumonia in young gay men. This condition was
subsequently determined to be AIDS, which in
turn was a result of infection with the human
immunodeficiency virus (HIV). AIDS reporting
started in 1981; by 1986, all 50 states, the
District of Columbia, and several U.S. dependent
areas had instituted AIDS case reporting.
Beginning in 1985, many states implemented HIV
case reporting as part of an integrated HIV and
AIDS surveillance system. As of 2008, all states
had implemented confidential, name-based HIV
reporting.
Process:
Using a uniform surveillance case definition and
report form, all 50 states, the District of
Columbia, and 6 U.S. dependent areas (American
Samoa, Guam, Northern Mariana Islands, Puerto
Rico, Republic of Palau, and the U.S. Virgin
Islands) report confirmed diagnoses of HIV
infection and AIDS to CDC. Case reports from
these jurisdictions are sent to CDC after
removal of personally identifying information.
Which jurisdictions participate: As of
April 2008, all jurisdictions had implemented
confidential name-based HIV infection reporting.
However, jurisdictions need to report 4 years of
name-based surveillance data to CDC before the
data can be statistically adjusted for reporting
delays and missing risk-factor information. The
2010 HIV Surveillance Report contains adjusted
data on diagnoses of HIV infection, regardless
of the stage of disease, from 46 states1
and 5 U.S. dependent areas (all but the Republic
of Palau). It contains AIDS diagnosis data from
50 states, the District of Columbia, and 6 U.S.
dependent areas.
What data are collected:
HIV reporting provides information on
demographic characteristics (i.e., sex,
race/ethnicity, age, and place of diagnosis),
transmission category (mode of exposure),
initial immune status, and viral load.
In addition, HIV case surveillance activities
allow jurisdictions to monitor HIV disease
progression and utilization of care services
through the ongoing collection of data on
laboratory test results (viral load and CD4
counts), opportunistic infections and illnesses,
and vital status.
The national HIV Surveillance Report is
published annually.
How this surveillance contributes to HIV prevention:
Case surveillance data provide the basis for our
understanding of the burden of disease and are
used to guide public health action at the
federal, state, and local levels. Knowing how
many people are diagnosed with HIV infection
each year—and their stage of disease at
diagnosis—is important for planning and resource
allocation and for monitoring trends and
disparities between groups.
HIV Incidence Surveillance
In 2004, as an extension of HIV case surveillance
activities, CDC first funded selected state and
local health departments to begin data collection
for HIV incidence surveillance.
Process:
State and local health departments that conduct
HIV incidence surveillance collect testing and
treatment history information as a part of
routine surveillance activities. These data are
sent to CDC after removal of personally
identifying information. In addition, incidence
surveillance coordinators at state and local
health departments work closely with
commercial/private, public, and hospital-based
laboratories to acquire leftover diagnostic
blood specimens to test for recent infection. By
applying additional tests to leftover blood
specimens from persons newly diagnosed with HIV
infection in the funded jurisdictions, CDC is
able to identify the number of new HIV
infections in a given year.
Which jurisdictions participate: Since
2008, HIV incidence surveillance areas have
included 25 jurisdictions.2
What data are collected:
In addition to data collected through case
surveillance, data on HIV testing behaviors and
results from tests for recent HIV infection,
collected from the jurisdictions participating
in HIV incidence surveillance, are used to
estimate HIV incidence. The incidence estimates,
which are stratified by age, race/ethnicity,
sex, and transmission category, describe the
number of new HIV infections in the United
States.
The data from the jurisdictions that conduct
incidence surveillance are extrapolated to yield
a national estimate. In 2011, CDC published
estimates indicating that HIV incidence has
remained essentially stable over the period
2006–2009. Read more about the HIV incidence
estimates.
How this surveillance contributes to HIV prevention:
Annual estimates of the number of new infections
in the U.S. can be used to monitor current
transmission patterns. Monitoring HIV incidence
is critical for allocating resources and
evaluating the effectiveness of HIV testing and
other prevention programs. Improved surveillance
methods allow us to better direct our programs
and resources to the populations most affected.
Variant, Atypical, and Resistant HIV Surveillance (VARHS)
Since
2004, as an extension of HIV case surveillance
activities, selected state and local health
departments have been funded to collect HIV
genetic sequence data to identify HIV subtypes
and the presence of drug resistance mutations
among persons newly diagnosed with HIV infection
who have never taken antiretroviral medications.
Process: Health department surveillance
staff partner with commercial/private, public,
and hospital-based laboratories to obtain
electronic genetic sequence data from genotype
testing that has been done as a part of HIV
care. Case reports from these jurisdictions are
sent to CDC after removal of personally
identifying information.
Which jurisdictions participate:
Currently, 11 jurisdictions3 are funded to
collect genetic sequence data to determine HIV-1
drug resistance and subtypes.
What data are collected:
In addition to data collected through case
surveillance, genetic sequence data are reported
to the state or local health department from
genotype testing conducted as a routine part of
HIV care.
VARHS data are published periodically. The 2006
data were published in the May 2010 issue of
AIDS (read the abstract). The 2007 data were presented in
February 2010 at the 17th Conference on
Retroviruses and Opportunistic Infections (read
the abstract).
How this surveillance contributes to HIV prevention:
Data from VARHS are used to monitor the
frequency of transmitted
drug-resistance-associated mutations and HIV
subtypes among persons for whom HIV infection is
newly diagnosed. These data provide information
on the variance of the transmitted strains of
HIV and the emergence of resistant strains. To
effectively monitor HIV drug resistance, state
and local surveillance systems must work with
laboratories in their jurisdictions to expand
their surveillance activities to include
reporting of HIV genomic data.
National HIV Behavioral Surveillance (NHBS)
In
2003, CDC created NHBS for conducting behavioral
surveillance among persons at high risk for HIV
infection.
Process: Surveillance is conducted in
rotating annual cycles in three different
populations at high risk for HIV: men who have
sex with men (MSM), injection drug users (IDUs),
and heterosexuals at increased risk for HIV
infection (HET). Before each NHBS cycle,
formative research is conducted to learn more
about the populations and collect data to help
with sampling procedures. MSM are sampled using
venue-based, time-space sampling methods. Health
department staff members first identify venues
frequented by MSM (e.g., bars, clubs,
organizations, and street locations) and days
and times when men frequent those venues. Venues
(and specific day/time periods) for recruitment
are chosen randomly each month. IDUs and
heterosexuals are recruited using
respondent-driven sampling, a type of chain
referral sampling. Health department staff
members select a small number of initial
participants, or “seeds,” who complete the
survey and recruit their peers to participate.
Recruitment and interviewing continue until the
target sample size is reached.
Trained interviewers in all NHBS jurisdictions
use a standardized anonymous questionnaire to
collect information on HIV-related risk behaviors,
HIV testing, and use of HIV prevention services. HIV
testing is also offered to all participants. During
each cycle, a minimum of 450 (for heterosexuals) to
500 (for MSM and IDUs) eligible persons from each
participating jurisdiction are interviewed and
tested for HIV infection. The first full round of
NHBS, which comprised all three cycles (MSM, IDU,
and HET), was conducted during 2003–2007. The second
round was conducted during 2008–2010, and the third
round began in January 2011.
Which jurisdictions participate: As of
2011, 20 jurisdictions4
with high AIDS prevalence
are funded to conduct NHBS. Many of the health
department grantees subcontract with local
health departments, universities, or
community-based organizations to implement NHBS
activities.
What data are collected: Data on
behavioral risks for HIV, HIV testing behaviors,
access to and use of prevention services, and
HIV testing results are collected.
Findings from the first NHBS round have been
published in several issues of CDC’s
Morbidity and Mortality Weekly Report (MMWR).
Additionally:
- In 2010, findings from the second cycle of
NHBS for MSM (NHBS-MSM) were published in the
September 24 issue of MMWR.
- In 2011, findings from the NHBS-MSM2 were
published in the
June 2011 MMWR issue commemorating the
30th year since the first HIV cases were reported
and in a surveillance summary published in
October 2011.
How this surveillance contributes to HIV prevention:
NHBS data are used to provide a behavioral
context for trends seen in HIV surveillance
data. They also describe populations at
increased risk for HIV infection and thus
provide an indication of the leading edge of the
epidemic. Through systematic surveillance in
groups at high risk for HIV infection, NHBS will
be critical for monitoring the impact of the
National HIV/AIDS Strategy, which focuses on
decreasing HIV incidence, improving linkage to
care, and reducing disparities.
Medical Monitoring Project (MMP)
In 2005, CDC implemented MMP, a supplemental
surveillance system designed to produce
nationally representative data on clinical and
behavioral outcomes among adults receiving
medical care for HIV infection in the U.S. and
Puerto Rico.
Process: MMP uses a 3-stage sampling
design to select an appropriate sample of
persons from which locally and nationally
representative data can be derived. The first
stage is selecting geographic areas to
participate; the second stage is selecting
outpatient facilities providing HIV medical care
within those participating project areas; and
the third stage is selecting patients at least
18 years of age who are receiving care at those
selected facilities. The annual sample of
facilities participating in MMP ranges from
600–800 health-care facilities. Approximately
9,000 patients from these facilities are sampled
annually. Trained MMP interviewers and
abstractors collect data through face-to-face
interviews and medical record abstraction.
Which jurisdictions participate:
Since 2009, 23 jurisdictions have been
conducting MMP activities.5 The MMP jurisdictions
include over 80% of the total cases of HIV
infection and AIDS in the United States.
What data are collected: The 45-minute
interview includes questions about demographics
(i.e., gender, age, and health insurance or
medical coverage), access to care, HIV treatment
and adherence to medications, drug and alcohol
use, sexual behavior, met and unmet needs for
social services, and receipt of prevention
counseling in a clinical setting. MMP
abstractors then collect additional information
on clinical outcomes, prescription of
antiretroviral therapy, and other health-care
services provided from patients’ medical charts.
The current 5-year MMP cycle extends through May
31, 2013. MMP publications include the
following.
How this surveillance contributes to HIV prevention:
MMP data provide national estimates of the
clinical and behavioral characteristics of
persons receiving HIV care. MMP data are used to
monitor the U.S. National HIV/AIDS Strategy goal
of increasing access to care and optimizing
health outcomes among persons living with HIV.
Prevention planning groups, policy leaders,
health-care providers, and people living with
HIV infection can use the data to inform HIV
prevention activities, highlight disparities in
care and services, identify unmet needs, and
evaluate services. The data are also used to
guide policy and funding decisions aimed at
reducing the spread of HIV and improving the
quality of care for people living with HIV
infection throughout the United States.
1Alabama; Alaska; Arizona;
Arkansas; California; Colorado; Connecticut;
Delaware; Florida; Georgia; Idaho; Illinois;
Indiana; Iowa; Kansas; Kentucky; Louisiana;
Maine; Michigan; Minnesota; Mississippi;
Missouri; Montana; Nebraska; New Hampshire; New
Jersey; New Mexico; New York; Nevada; North
Carolina; North Dakota; Ohio; Oklahoma; Oregon;
Pennsylvania; Rhode Island; South Carolina;
South Dakota; Tennessee; Texas; Utah; Virginia;
Washington; West Virginia; Wisconsin; and
Wyoming.
2Incidence surveillance:
Alabama; Arizona; California; Chicago; Colorado;
Connecticut; District of Columbia; Florida; Houston;
Indiana; Los Angeles County; Louisiana;
Massachusetts; Michigan; Mississippi; New Jersey;
New York; New York City; North Carolina;
Philadelphia; San Francisco; South Carolina; Texas;
Virginia; and Washington.
3VARHS: Chicago; Colorado;
Connecticut; Florida; Los Angeles County;
Louisiana; Michigan; New York City; South
Carolina; Texas; and Washington.
4NHBS: Atlanta, GA; Baltimore, MD; Boston MA;
Chicago, IL; Dallas, TX; Denver, CO; Detroit, MI;
Houston, TX; Los Angeles, CA; Miami, FL; Nassau, NY;
New Orleans, LA; New York, NY; Newark, NY;
Philadelphia, PA; San Diego, CA; San Francisco, CA;
San Juan, PR; Seattle, WA; and Washington, DC.
5California; Chicago,
Illinois; Delaware; Florida; Georgia; Houston,
Texas; Illinois; Indiana; Los Angeles County,
California; Michigan; Mississippi; New Jersey;
the state of New York; New York City, New York;
North Carolina; Oregon; Pennsylvania;
Philadelphia, Pennsylvania; Puerto Rico; San
Francisco, California; Texas; Virginia; and
Washington. |